XERS Xeris Biopharma Holdings, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Commercial-stage biopharma focused on therapies for chronic endocrine and neurological diseases in the U.S., with three commercial products: Recorlev, Gvoke, Keveyis
• • Phase 3-ready XP-8121: once-weekly subcutaneous levothyroxine injection leveraging proprietary XeriSol tech, planned Phase 3 start in 2026
• • Strategic emphasis on pipeline leveraging proprietary non-aqueous formulation tech (XeriSol/XeriJect) for improved drug delivery and new licensing partnerships
• • Patent protection for key products: Recorlev (orphan drug exclusivity through 2028, patents to 2040), Gvoke patents to 2036; Keveyis lost orphan exclusivity in 2022, facing generic competition
• • Noteworthy: Positive Phase 2 data for XP-8121 with 72% patient preference for weekly injection; FDA agreed on single non-inferiority Phase 3 trial design

Risk Factors

• • Risk of SBA PPP Loan audit/enforcement under CARES Act until May 2026, potentially diverting management resources and incurring costs
• • Geopolitical and macroeconomic risks impairing capital access due to inflation, interest rates, bank failures, and financial market volatility
• • Supply chain and inventory risks with potential product returns exceeding reserves, reliant on third-party data accuracy for return estimates
• • Competitive threats to Recorlev from Corcept Therapeutics' Korlym, Recordati's Signifor LAR and Isturisa, and potential ketoconazole approval in US
• • Financial risk from $200M term loans and $33.6M 8.00% Convertible Notes secured by company assets, with restrictive covenants limiting operations

Management Discussion & Analysis

• • No revenue or profitability figures disclosed in the provided MD&A section
• • Financing cash inflow $11.4M in 2025 vs $36.2M in 2024; driven by $20.7M stock awards and $10.9M stock repurchases
• • Investing cash outflow $696K in 2025 vs inflow $4.9M in 2024 due to fewer short-term investment purchases
• • No segment performance data or forward-looking guidance included in the excerpt

What are the latest XERS SEC filings in 2026?

Xeris Biopharma Holdings, Inc. (XERS) has filed a 10-K annual report on March 2, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 6, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did XERS file its most recent 10-K annual report?

Xeris Biopharma Holdings, Inc. (XERS) filed its most recent 10-K annual report on March 2, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view XERS 10-Q quarterly reports?

Xeris Biopharma Holdings, Inc. (XERS)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every XERS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has XERS filed recently?

Xeris Biopharma Holdings, Inc. (XERS)'s most recent 8-K was filed on August 6, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find XERS insider trading activity (Form 4)?

SignalX aggregates every XERS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does XERS file with the SEC?

Xeris Biopharma Holdings, Inc. (XERS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new XERS filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Xeris Biopharma Holdings, Inc. (XERS).

What is XERS's SEC CIK number?

Xeris Biopharma Holdings, Inc. (XERS)'s SEC CIK (Central Index Key) number is 1867096. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1867096 to look up all XERS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find XERS return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Xeris Biopharma Holdings, Inc. (XERS) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.